Remove 2004 Remove Doctors Remove Pharma
article thumbnail

New Prescription Migraine Drugs Aren’t Resonating with Patients—Here’s How Pharma Can Boost Uptake

PM360

Despite a slew of prescription options and widespread advertising pushes, most patients are sticking with over-the-counter (OTC) remedies rather than trying new preventive medications, according to Phreesia Life Sciences’ survey results collected from more than 4,000 patients checking in for their doctors’ appointments in July 2021.

article thumbnail

Delivering Improved Disease Awareness Through More Strategic Partnerships

PM360

Can more than 20 pharma companies unite around messaging for biomarker testing even though everyone seems to call it something different? Historically, pharma companies only do marketing for biomarker testing related to the type of drug they were launching,” says Nikki Martin, Senior Director, Precision Medicine Initiatives, LUNGevity. “As

Education 105
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

The Dark Side of KOL Relationship

Contrarian Sales Techniques

It was marketed aggressively to doctors and was touted as a safer alternative to other pain relievers on the market. However, it was later discovered that the drug increased the risk of heart attacks and strokes, and it was eventually pulled from the market in 2004. Another example is the case of Purdue Pharma and the opioid crisis.

Ethics 52
article thumbnail

Uri Goren

Cadensee

It's become the main thing that the doctors are looking at now. When he was going through his cancer, he died in 2004. It broke the confines of you being a doctor learning healthcare, learning to be a medical profession and that stayed there; it just broke it all. Interview Transcription (mild edits). And that's how it started.

article thumbnail

Pharma’s addiction to McKinsey

World of DTC Marketing

One likened the firm’s earnings from advising Purdue Pharma and other pharmaceutical companies to “blood money” from drug traffickers. Yet, pharma continues to be aligned with MBA spreadsheet consulting. I couldn’t believe what I heard during a McKinsey report on a pharma company’s oncology drug.